AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26208687 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal zinc supplementation (20 mg/day elemental zinc)
Number of subjects: 39
Study 26208687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 24509405 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom gutter splint worn nightly for 3 months on the intervention joint
Number of subjects: 26
Study 23519656 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR) 4 mg
Number of subjects: 38
Study 23519656 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate extended release (MPH) 36 mg
Number of subjects: 38
Study 23519656 — intervention group
Group type: EXPERIMENTAL
Intervention: GXR and MPH combined
Number of subjects: 38
Study 23519656 — intervention group
Group type: COMPARATOR
Intervention: GXR, MPH, and GXR and MPH combined
Number of subjects: 38
Study 21206549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (SXB) 9 g nightly
Number of subjects: 228
Study 21206549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (SXB) 6 g and 9 g nightly
Number of subjects: 228
Study 21206549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (SXB) (all doses)
Number of subjects: 228
Study 21206549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (SXB)
Number of subjects: 228
Study 21206549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 18386647 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 18386647 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16360267 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic back pain patients
Number of subjects: 11
Study 16360267 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 11
Study 14556820 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) for 20 weeks
Number of subjects: 16
Study 14556820 — intervention group
Group type: COMPARATOR
Intervention: Observation for 20 weeks
Number of subjects: 16
Study 10617701 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplemented formula
Number of subjects: 21
Study 10617701 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA + arachidonic acid supplemented formula
Number of subjects: 21
Study 10617701 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no LCPUFA)
Number of subjects: 21
Study 10617701 — intervention group
Group type: COMPARATOR
Intervention: Breastfed infants
Number of subjects: 21
Study 10617701 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed infants (all groups)
Number of subjects: 21
Study 8937798 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous plasma glucose measurements
Number of subjects: 9
Study 8937798 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Arterialized' venous ('heated-hand' technique) plasma glucose measurements
Number of subjects: 9
Study 8937798 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary plasma glucose measurements
Number of subjects: 9
Study 7956390 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (40 mg)
Number of subjects: 24
Study 7956390 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled metaproterenol (15 mg)
Number of subjects: 24
Study 7956390 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of furosemide (40 mg) and metaproterenol (15 mg)
Number of subjects: 24
Study 3674548 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐ or high‐dose epimestrol administration schedule
Number of subjects: 52
Study 3674548 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary progesterone levels in women with infertility
Number of subjects: 52
Study 3674548 — intervention group
Group type: COMPARATOR
Intervention: Salivary progesterone levels in eugonadal women
Number of subjects: 52
Study 3674548 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva/plasma progesterone ratio
Number of subjects: 52
Study 26836963 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Incision Laparoscopic Percutaneous Extraperitoneal Closure (SILPEC)
Number of subjects: 109
Study 26836963 — intervention group
Group type: COMPARATOR
Intervention: Conventional Laparoscopic Percutaneous Closure (LPEC)
Number of subjects: 109
Study 24105358 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing Touch (HT)
Number of subjects: 41
Study 24105358 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (Control)
Number of subjects: 41
Study 23632052 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block with clonidine
Number of subjects: 60
Study 20888186 — intervention group
Group type: EXPERIMENTAL
Intervention: ET OLT
Number of subjects: 46
Study 20888186 — intervention group
Group type: EXPERIMENTAL
Intervention: ET OLT+MI
Number of subjects: 46
Study 20888186 — intervention group
Group type: COMPARATOR
Intervention: Placebo control OLT
Number of subjects: 46
Study 18928378 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir, 500 mg twice daily
Number of subjects: 20
Study 18928378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16642611 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus Chinese medicine
Number of subjects: 86
Study 16642611 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture plus Chinese medicine
Number of subjects: 86
Study 12809175 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 6
Study 12809175 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 pg/kg/die of rhGH (GH2.5)
Number of subjects: 6
Study 12809175 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.3 pg/kg/die of rhGH (GH3.3)
Number of subjects: 6
Study 10801246 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (150 microg desogestrel and 30 microg ethinyl estradiol)
Number of subjects: 40
Study 10801246 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no oral contraceptive)
Number of subjects: 40
Study 8715782 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic clinical supervision
Number of subjects: 33
Study 8715782 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 33
Study 1433426 — intervention group
Group type: EXPERIMENTAL
Intervention: 975 mg aspirin 30 min after 10 g activated charcoal
Number of subjects: 15
Study 1433426 — intervention group
Group type: EXPERIMENTAL
Intervention: 975 mg aspirin 60 min after 10 g activated charcoal
Number of subjects: 15
Study 1433426 — intervention group
Group type: COMPARATOR
Intervention: 975 mg aspirin alone
Number of subjects: 15
Study 3812052 — intervention group
Group type: EXPERIMENTAL
Intervention: High-nicotine cigarettes (0.9 mg)
Number of subjects: 42
Study 3812052 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-nicotine cigarettes (0.002 mg)
Number of subjects: 42
Study 3812052 — intervention group
Group type: COMPARATOR
Intervention: Control (candy)
Number of subjects: 42
Study 31223067 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality Salience (MS) condition
Number of subjects: 170
Study 31223067 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic accidents MS condition
Number of subjects: 170
Study 31223067 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 170
Study 29384337 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education delivered through e-learning with online reports and behavioural feedback for the experimental group.
Number of subjects: 95
Study 29384337 — intervention group
Group type: COMPARATOR
Intervention: Control group without online reports and behavioural feedback.
Number of subjects: 95
Study 26540397 — intervention group
Group type: EXPERIMENTAL
Intervention: IV haloperidol 1 mg every 6 hours
Number of subjects: 68
Study 26540397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 24755126 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (1.25 mg/day, with possible increase to 1.75-2.25 mg/day based on INR)
Number of subjects: 101
Study 24755126 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg/day)
Number of subjects: 101
Study 24755126 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 101
Study 24755126 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 101
Study 22995458 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotated head position (>45° head turn)
Number of subjects: 80
Study 22995458 — intervention group
Group type: COMPARATOR
Intervention: Neutral head position
Number of subjects: 80
Study 20435294 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (n = 59)
Number of subjects: 109
Study 17916662 — intervention group
Group type: EXPERIMENTAL
Intervention: BH(4) (400 mg twice daily)
Number of subjects: 22
Study 17916662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16358138 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (twice a day)
Number of subjects: 25
Study 16358138 — intervention group
Group type: COMPARATOR
Intervention: Control (no inspiratory muscle training)
Number of subjects: 25
Study 12756078 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg)
Number of subjects: 0
Study 12756078 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (20 mg once daily)
Number of subjects: 0
Study 10625125 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone contact
Number of subjects: 143
Study 10625125 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing
Number of subjects: 143
Study 10625125 — intervention group
Group type: COMPARATOR
Intervention: Direct mail
Number of subjects: 143
Study 8619011 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patches (17.5 mg)
Number of subjects: 16
Study 8619011 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 16
Study 1664253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (Fragmin) 2,500 XaI U 2 h before operation
Number of subjects: 24
Study 1664253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (Fragmin) 5,000 XaI U 10 h before surgery
Number of subjects: 24
Study 1664253 — intervention group
Group type: COMPARATOR
Intervention: Unfragmented heparin (UH) 5,000 IU before operation
Number of subjects: 24
Study 7032413 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (500 mg infusion over 30 minutes before surgery)
Number of subjects: 223
Study 7032413 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control group)
Number of subjects: 223
Study 31489852 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐PRF+
Number of subjects: 40
Study 31489852 — intervention group
Group type: COMPARATOR
Intervention: Control (saline only)
Number of subjects: 40
Study 29131124 — intervention group
Group type: EXPERIMENTAL
Intervention: levofloxacin-containing bismuth quadruple therapy (RBAL)
Number of subjects: 329
Study 29131124 — intervention group
Group type: EXPERIMENTAL
Intervention: standard bismuth quadruple therapy (RBMT)
Number of subjects: 329
Study 29131124 — intervention group
Group type: EXPERIMENTAL
Intervention: levofloxacin-containing triple therapy (RAL)
Number of subjects: 329
Study 25727139 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) for 1 hour at 20Hz
Number of subjects: 36
Study 25727139 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 36
Study 25727139 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES)
Number of subjects: 36
Study 23998516 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (35,000 IU/wk)
Number of subjects: 145
Study 23998516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 21248398 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid with ketorolac (3 weekly injections of HA with ketorolac followed by 2 weekly injections of HA)
Number of subjects: 43
Study 21248398 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular hyaluronic acid alone (5 weekly injections of HA)
Number of subjects: 43
Study 19685727 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment applied to Baihui (GV 20), Danzhong (CV 17), Zhongwan (CV 12) for 14 sessions, once every other day.
Number of subjects: 70
Study 19685727 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoints (2 cm from the specified acupoints) for 14 sessions, once every other day.
Number of subjects: 70
Study 17699988 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 1.875 mg/kg alone (Group B)
Number of subjects: 120
Study 17699988 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 1.875 mg/kg with 2 microg/kg neostigmine (Group BN 2)
Number of subjects: 120
Study 17699988 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 1.875 mg/kg with 3 microg/kg neostigmine (Group BN 3)
Number of subjects: 120
Study 17699988 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 1.875 mg/kg with 4 microg/kg neostigmine (Group BN 4)
Number of subjects: 120
Study 17699988 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 15336476 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis
Number of subjects: 548
Study 15336476 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 548
Study 11426767 — intervention group
Group type: EXPERIMENTAL
Intervention: DHCA alone
Number of subjects: 30
Study 11426767 — intervention group
Group type: EXPERIMENTAL
Intervention: DHCA plus retrograde brain perfusion (RBP)
Number of subjects: 30
Study 11426767 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade perfusion (ANTE)
Number of subjects: 30
Study 11426767 — intervention group
Group type: COMPARATOR
Intervention: Coronary bypass (CAB) control
Number of subjects: 30
Study 11426767 — intervention group
Group type: EXPERIMENTAL
Intervention: DHCA
Number of subjects: 30
Study 11426767 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP
Number of subjects: 30
Study 11426767 — intervention group
Group type: EXPERIMENTAL
Intervention: ANTE
Number of subjects: 30
Study 11426767 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 11426767 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiarch repairs with DHCA
Number of subjects: 30
Study 11426767 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiarch repairs with ANTE
Number of subjects: 30
Study 10731735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 64
Study 10731735 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 64
Study 7973143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact whole milk (360 mL)
Number of subjects: 205
Study 7973143 — intervention group
Group type: COMPARATOR
Intervention: 90% lactose-hydrolyzed milk (360 mL)
Number of subjects: 205
Study 2537239 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tar treatment
Number of subjects: 56
Study 2537239 — intervention group
Group type: COMPARATOR
Intervention: PUVA treatment
Number of subjects: 56
Study 2537239 — intervention group
Group type: COMPARATOR
Intervention: UVB treatment
Number of subjects: 56
Study 2537239 — intervention group
Group type: COMPARATOR
Intervention: Untreated psoriatics
Number of subjects: 56
Study 2537239 — intervention group
Group type: COMPARATOR
Intervention: Normal healthy volunteers
Number of subjects: 56
Study 793565 — intervention group
Group type: EXPERIMENTAL
Intervention: Duopect (narcotine hydrochloride + glyceryl guiacolate)
Number of subjects: 62
Study 793565 — intervention group
Group type: COMPARATOR
Intervention: Narcotine
Number of subjects: 62
Study 793565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 31852380 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 or 300 μg/kg of rVIIa-FP
Number of subjects: 9
Study 31852380 — intervention group
Group type: EXPERIMENTAL
Intervention: rVIIa-FP
Number of subjects: 9
Study 31852380 — intervention group
Group type: COMPARATOR
Intervention: rFVIIa (eptacog alfa)
Number of subjects: 9
Study 30582447 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nebulized albuterol
Number of subjects: 30
Study 30582447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28126423 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT application with tension)
Number of subjects: 16
Study 28126423 — intervention group
Group type: COMPARATOR
Intervention: Sham (non-elastic tape application without tension)
Number of subjects: 16
Study 25926678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine 5 mg twice a day + standard medical therapy (bisoprolol 1.25 mg once daily)
Number of subjects: 81
Study 25926678 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (bisoprolol 2.5 to 3.75 mg once daily)
Number of subjects: 81
Study 23356124 — intervention group
Group type: EXPERIMENTAL
Intervention: Polar FA20 accelerometer (PA)
Number of subjects: 28
Study 23356124 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 28
Study 22488183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold fluid (2°C)
Number of subjects: 7
Study 22488183 — intervention group
Group type: COMPARATOR
Intervention: Control fluid (37°C)
Number of subjects: 7
Study 19235853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal influenza vaccination with half the antigenic content
Number of subjects: 0
Study 19235853 — intervention group
Group type: COMPARATOR
Intervention: Conventional intramuscular vaccination
Number of subjects: 0
Study 16534045 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist counseling at discharge and a follow-up telephone call 3 to 5 days later.
Number of subjects: 178
Study 16534045 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pharmacist counseling).
Number of subjects: 178
Study 14515043 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor V Leiden mutation
Number of subjects: 0
Study 14515043 — intervention group
Group type: COMPARATOR
Intervention: Venous thromboembolism
Number of subjects: 0
Study 11144401 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir oral suspension
Number of subjects: 715
Study 11144401 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate potassium, cefprozil, azithromycin (Control)
Number of subjects: 715
Study 9058627 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal enemas containing butyrate
Number of subjects: 0
Study 9058627 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal enemas containing a mixture of short-chain fatty acids (SCFAs)
Number of subjects: 0
Study 9058627 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (control)
Number of subjects: 0
Study 7940601 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of vitamin-C administration
Number of subjects: 10
Study 7940601 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal hepatic function)
Number of subjects: 10
Study 3763291 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV vaccine
Number of subjects: 100
Study 3763291 — intervention group
Group type: COMPARATOR
Intervention: MMR + V vaccine
Number of subjects: 100
Study 30580974 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily preventive zinc tablets (7 mg/d)
Number of subjects: 3407
Study 30580974 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐zinc, low‐iron micronutrient powder (10 mg/d zinc, 6 mg/d iron, and 13 other micronutrients)
Number of subjects: 3407
Study 30580974 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic zinc supplementation for diarrhea (20 mg/d for 10 days per episode)
Number of subjects: 3407
Study 30580974 — intervention group
Group type: COMPARATOR
Intervention: Daily placebo powder
Number of subjects: 3407
Study 29257995 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting stress, parent perceived child vulnerability, parental hostility towards the child, lower educational levels of the mother
Number of subjects: 59
Study 29257995 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of the child
Number of subjects: 59
Study 25787216 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab monotherapy
Number of subjects: 34
Study 25787216 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab combined with photodynamic therapy (PDT)
Number of subjects: 34
Study 25787216 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Ranibizumab monotherapy and combination therapy)
Number of subjects: 34
Study 25787216 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (PDT)
Number of subjects: 34
Study 25787216 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline BCVA and integrity of IS/OS junction at month 12
Number of subjects: 34
Study 25787216 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 34
Study 25326876 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive portfolio diet
Number of subjects: 351
Study 25326876 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine portfolio diet
Number of subjects: 351
Study 25326876 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 351
Study 22042366 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicin and fluorouracil (CEF)
Number of subjects: 639
Study 22042366 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate and fluorouracil (CMF)
Number of subjects: 639
Study 20381283 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin genotyping
Number of subjects: 896
Study 20381283 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin genotyping (per-protocol analysis)
Number of subjects: 896
Study 20381283 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 896
Study 18060244 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (ASA and clopidogrel)
Number of subjects: 0
Study 18060244 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0
Study 18060244 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized fixed dose antiplatelet therapy
Number of subjects: 0
Study 18060244 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual determination of platelet function
Number of subjects: 0